{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:16:18Z","timestamp":1769170578397,"version":"3.49.0"},"reference-count":41,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"SBP\u2019s NCI Cancer Center","doi-asserted-by":"publisher","award":["P30 CA030199"],"award-info":[{"award-number":["P30 CA030199"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Acute leukemia is a particularly problematic collection of hematological cancers, and, while somewhat rare, the survival rate of patients is typically abysmal without bone marrow transplantation. Furthermore, traditional chemotherapies used as standard-of-care for patients cause significant side effects. Understanding the evolution of leukemia to identify novel targets and, therefore, drug treatment regimens is a significant medical need. Genomic rearrangements and other structural variations (SVs) have long been known to be causative and pathogenic in multiple types of cancer, including leukemia. These SVs may be involved in cancer initiation, progression, clonal evolution, and drug resistance, and a better understanding of SVs from individual patients may help guide therapeutic options. Here, we show the utilization of optical genome mapping (OGM) to detect known and novel SVs in the samples of patients with leukemia. Importantly, this technology provides an unprecedented level of granularity and quantitation unavailable to other current techniques and allows for the unbiased detection of novel SVs, which may be relevant to disease pathogenesis and\/or drug resistance. Coupled with the chemosensitivities of these samples to FDA-approved oncology drugs, we show how an impartial integrative analysis of these diverse datasets can be used to associate the detected genomic rearrangements with multiple drug sensitivity profiles. Indeed, an insertion in the gene MUSK is shown to be associated with increased sensitivity to the clinically relevant agent Idarubicin, while partial tandem duplication events in the KMT2A gene are related to the efficacy of another frontline treatment, Cytarabine.<\/jats:p>","DOI":"10.3390\/cancers16020418","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T11:28:46Z","timestamp":1705577326000},"page":"418","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Detection of Genomic Structural Variations Associated with Drug Sensitivity and Resistance in Acute Leukemia"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8718-9453","authenticated-orcid":false,"given":"Darren","family":"Finlay","sequence":"first","affiliation":[{"name":"NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5297-8307","authenticated-orcid":false,"given":"Rabi","family":"Murad","sequence":"additional","affiliation":[{"name":"NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2821-8437","authenticated-orcid":false,"given":"Karl","family":"Hong","sequence":"additional","affiliation":[{"name":"Bionano Genomics Inc., San Diego, CA 92121, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3492-1102","authenticated-orcid":false,"given":"Joyce","family":"Lee","sequence":"additional","affiliation":[{"name":"Bionano Genomics Inc., San Diego, CA 92121, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy Wing Chun","family":"Pang","sequence":"additional","affiliation":[{"name":"Bionano Genomics Inc., San Diego, CA 92121, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Yu","family":"Lai","sequence":"additional","affiliation":[{"name":"Bionano Genomics Inc., San Diego, CA 92121, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Clifford","sequence":"additional","affiliation":[{"name":"Bionano Genomics Inc., San Diego, CA 92121, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Burian","sequence":"additional","affiliation":[{"name":"Scripps MD Anderson, La Jolla, CA 92037, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Mason","sequence":"additional","affiliation":[{"name":"Scripps MD Anderson, La Jolla, CA 92037, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5829-2649","authenticated-orcid":false,"given":"Alex R.","family":"Hastie","sequence":"additional","affiliation":[{"name":"Bionano Genomics Inc., San Diego, CA 92121, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Yin","sequence":"additional","affiliation":[{"name":"NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristiina","family":"Vuori","sequence":"additional","affiliation":[{"name":"NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/nature07485","article-title":"DNA sequencing of a cytogenetically normal acute myeloid leukemia genome","volume":"456","author":"Ley","year":"2008","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/MOH.0000000000000567","article-title":"Driver mutations in acute myeloid leukemia","volume":"27","author":"Kishtagari","year":"2020","journal-title":"Curr. Opin. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.ajhg.2021.06.001","article-title":"Next-generation cytogenetics: Comprehensive assessment of 52 hematological malignancy genomes by optical genome mapping","volume":"108","author":"Neveling","year":"2021","journal-title":"Am. J. Hum. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nature20098","article-title":"De novo assembly and phasing of a Korean human genome","volume":"538","author":"Seo","year":"2016","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/jmedgenet-2019-106078","article-title":"Single-molecule optical mapping enables quantitative measurement of D4Z4 repeats in facioscapulohumeral muscular dystrophy (FSHD)","volume":"57","author":"Dai","year":"2020","journal-title":"J. Med. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.jmoldx.2021.07.021","article-title":"Validation of Optical Genome Mapping for the Molecular Diagnosis of Facioscapulohumeral Muscular Dystrophy","volume":"23","author":"Stence","year":"2021","journal-title":"J. Mol. Diagn."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13073-017-0479-0","article-title":"Next-generation mapping: A novel approach for detection of pathogenic structural variants with a potential utility in clinical diagnosis","volume":"9","author":"Barseghyan","year":"2017","journal-title":"Genome Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Soto, D.C., Shew, C., Mastoras, M., Schmidt, J.M., Sahasrabudhe, R., Kaya, G., Andr\u00e9s, A.M., and Dennis, M.Y. (2020). Identification of Structural Variation in Chimpanzees Using Optical Mapping and Nanopore Sequencing. Genes, 11.","DOI":"10.3390\/genes11030276"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"eaar6343","DOI":"10.1126\/science.aar6343","article-title":"High-resolution comparative analysis of great ape genomes","volume":"360","author":"Kronenberg","year":"2018","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/s41588-018-0195-8","article-title":"Integrative detection and analysis of structural variation in cancer genomes","volume":"50","author":"Dixon","year":"2018","journal-title":"Nat. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"23588","DOI":"10.18632\/oncotarget.15802","article-title":"Next generation mapping reveals novel large genomic rearrangements in prostate cancer","volume":"8","author":"Jaratlerdsiri","year":"2017","journal-title":"Oncotarget"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1101\/gr.227975.117","article-title":"Optical mapping reveals a higher level of genomic architecture of chained fusions in cancer","volume":"28","author":"Chan","year":"2018","journal-title":"Genome Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"474.1","DOI":"10.1096\/fasebj.2019.33.1_supplement.474.1","article-title":"An Integrated Framework for Genome Analysis Reveals Numerous Previously Unrecognizable Structural Variants in Leukemia Patient Samples","volume":"33","author":"Broach","year":"2019","journal-title":"FASEB J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1038\/s41375-022-01652-8","article-title":"High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance","volume":"36","author":"Yang","year":"2022","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Suttorp, J., L\u00fchmann, J.L., Behrens, Y.L., G\u00f6hring, G., Steinemann, D., Reinhardt, D., Neuhoff, N.V., and Schneider, M. (2022). Optical Genome Mapping as a Diagnostic Tool in Pediatric Acute Myeloid Leukemia. Cancers, 14.","DOI":"10.3390\/cancers14092058"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Puiggros, A., Ramos-Campoy, S., Kamaso, J., de la Rosa, M., Salido, M., Melero, C., Rodr\u00edguez-Rivera, M., Bougeon, S., Collado, R., and Gimeno, E. (2022). Optical Genome Mapping: A Promising New Tool to Assess Genomic Complexity in Chronic Lymphocytic Leukemia (CLL). Cancers, 14.","DOI":"10.3390\/cancers14143376"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Valkama, A., Vorimo, S., Kumpula, T., R\u00e4s\u00e4nen, H., Savolainen, E.R., Pylk\u00e4s, K., and Mantere, T. (2023). Optical Genome Mapping as an Alternative to FISH-Based Cytogenetic Assessment in Chronic Lymphocytic Leukemia. Cancers, 15.","DOI":"10.3390\/cancers15041294"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Soler, G., Ouedraogo, Z., Goumy, C., Lebecque, B., Aspas Requena, G., Ravinet, A., Kanold, J., V\u00e9ron\u00e8se, L., and Tchirkov, A. (2023). Optical Genome Mapping in Routine Cytogenetic Diagnosis of Acute Leukemia. Cancers, 15.","DOI":"10.3390\/cancers15072131"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Tembrink, M., Gerding, W., Wieczorek, S., Mika, T., Schroers, R., Nguyen, H.P., Vangala, D.B., and Nilius-Eliliwi, V. (2023). Novel NUP98::ASH1L Gene Fusion in Acute Myeloid Leukemia Detected by Optical Genome Mapping. Cancers, 15.","DOI":"10.3390\/cancers15112942"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Sahajpal, N., Mondal, A., Singh, H., Vashisht, A., Ananth, S., Saul, D., Hastie, A.R., Hilton, B., DuPont, B.R., and Savage, N.M. (2023). Clinical Utility of Optical Genome Mapping and 523-Gene Next Generation Sequencing Panel for Comprehensive Evaluation of Myeloid Cancers. Cancers, 15.","DOI":"10.3390\/cancers15123214"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Gigu\u00e8re, A., Raymond-Bouchard, I., Collin, V., Claveau, J.S., H\u00e9bert, J., and LeBlanc, R. (2023). Optical Genome Mapping Reveals the Complex Genetic Landscape of Myeloma. Cancers, 15.","DOI":"10.3390\/cancers15194687"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1158\/0008-5472.CAN-20-1655","article-title":"Functional precision medicine identifies new therapeutic candidates for medulloblastoma","volume":"80","author":"Rusert","year":"2020","journal-title":"Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1038\/s41467-021-25664-7","article-title":"The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitor","volume":"12","author":"Khateb","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/neuonc\/noab001","article-title":"PTEN deficiency leads to proteasome addiction, a novel vulnerability in Glioblastoma","volume":"23","author":"Benitez","year":"2021","journal-title":"Neuro Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/gcc.22971","article-title":"Optical genome mapping, a promising alternative to gold standard cytogenetic approaches in a series of acute lymphoblastic leukemias","volume":"60","author":"Lestringant","year":"2021","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"L\u00fchmann, J.L., Stelter, M., Wolter, M., Kater, J., Lentes, J., Bergmann, A.K., Schieck, M., G\u00f6hring, G., M\u00f6ricke, A., and Cario, G. (2021). The Clinical Utility of Optical Genome Mapping for the Assessment of Genomic Aberrations in Acute Lymphoblastic Leukemia. Cancers, 13.","DOI":"10.3390\/cancers13174388"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/ijc.33942","article-title":"Optical genome mapping reveals additional prognostic information compared to conventional cytogenetics in AML\/MDS patients","volume":"150","author":"Gerding","year":"2022","journal-title":"Int. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.26487","article-title":"Optimizing the diagnostic workflow for acute lymphoblastic leukemia by optical genome mapping","volume":"97","author":"Rack","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.jmoldx.2022.09.009","article-title":"Clinical Validation and Diagnostic Utility of Optical Genome Mapping for Enhanced Cytogenomic Analysis of Hematological Neoplasms","volume":"24","author":"Sahajpal","year":"2022","journal-title":"J. Mol. Diagn."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41375-022-01763-2","article-title":"Optical Genome Mapping in MDS and AML as tool for structural variant profiling-comment and data update on Yang et al.: \u201cHigh-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance\u201d","volume":"37","author":"Vangala","year":"2023","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Vieler, L.M., Nilius-Eliliwi, V., Schroers, R., Vangala, D.B., Nguyen, H.P., and Gerding, W.M. (2023). Optical Genome Mapping Reveals and Characterizes Recurrent Aberrations and New Fusion Genes in Adult ALL. Genes, 14.","DOI":"10.3390\/genes14030686"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Nilius-Eliliwi, V., Gerding, W.M., Schroers, R., Nguyen, H.P., and Vangala, D.B. (2023). Optical Genome Mapping for Cytogenetic Diagnostics in AML. Cancers, 15.","DOI":"10.3390\/cancers15061684"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1182\/bloodadvances.2022007583","article-title":"Optical genome mapping in acute myeloid leukemia: A multicenter evaluation","volume":"7","author":"Levy","year":"2023","journal-title":"Blood Adv."},{"key":"ref_35","unstructured":"Wapner, J. (2014). The Philadelphia Chromosome: A Genetic Mystery, a Lethal Cancer, and the Improbable Invention of a Lifesaving Treatment, The Experiment, LLC."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ng.3230","article-title":"The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias","volume":"47","author":"Andersson","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/cpt.553","article-title":"Targeting BCL2 with BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies","volume":"101","author":"Roberts","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd.2016.253","article-title":"From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors","volume":"16","author":"Ashkenazi","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Vanhuele, S., Kirova, Y., Hamy-Petit, A.-S., Rapinat, A., Gentien, D., Reyal, F., Vincent-Salomon, A., Eeckhoutte, A., Rodrigues, M., and Popova, T. (2022). Optical Genome Mapping for detecting Homologous Recombination Deficiency (HRD) in human breast cancers. bioRxiv.","DOI":"10.1101\/2022.12.23.521790"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.leukres.2014.06.007","article-title":"Orphan drug designation for pracinostat, volasertib and alvocidib in AML","volume":"38","author":"Bose","year":"2014","journal-title":"Leuk. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3324\/haematol.11068","article-title":"Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: The BGMT 95 trial results","volume":"92","author":"Pigneux","year":"2007","journal-title":"Haematologica"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/2\/418\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:49:58Z","timestamp":1760104198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/2\/418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["cancers16020418"],"URL":"https:\/\/doi.org\/10.3390\/cancers16020418","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,18]]}}}